Draft US Treasury COINS rules could sharply curtail China biotech deals

· Health · United States · China

Draft regulations from the US Treasury Department have triggered intense debate over the future of China biotech deals, which could be sharply curtailed under the proposal as written. The draft reportedly bars certain US investments and transactions tied to Chinese biotech. The proposal is one of the policy threads in the broader debate over US-China technology ties, and industry participants are weighing how strictly the rules would be applied and which deal structures would be affected. The outcome matters for companies that depend on cross-border licensing, manufacturing and research partnerships with Chinese firms.

Why it matters：Cross-border licensing and manufacturing links with China are embedded in many drugmakers' pipelines, so the final shape of these investment rules could force companies to restructure sourcing and partnership strategies.

Key points

  • The draft comes from the US Treasury Department.
  • As written, it could sharply curtail China biotech deals.
  • The debate is part of wider scrutiny of US-China technology ties.

Sources (original reporting)

More stories from this day